New medications show promise for children with rare liver disease
While different types of progressive familial intrahepatic cholestasis (PFIC) vary in their genetic cause and clinical profile, new medications like Bylvay (odevixibat) and Livmarli…
Lila Levinson, PhD, Science Writer—
Articles by Lila Levinson, PhD
Targeting mitochondrial problems eases cholestasis in mouse model
Problems in mitochondria, the cell’s powerhouses, may contribute to liver damage associated with cholestasis and represent a potential therapeutic target, a study showed. Deteriorating…
Drug for fatty liver disease MASH may help prevent transplants
Regulators in the European Union (EU) have granted conditional approval to Rezdiffra (resmetirom) for some people with metabolic dysfunction-associated steatohepatitis (MASH), making it the first…
Chemomab, FDA align on key aspects of nebokitug development
Chemomab Therapeutics has aligned with U.S. regulators on several aspects of the late-stage development of nebokitug, its candidate therapy for primary sclerosing cholangitis (PSC),…
Maternal liver damage markers can predict twin pregnancy outcomes
High maternal levels of liver damage markers in the blood can predict poor fetal outcomes in twin pregnancies affected by intrahepatic cholestasis of pregnancy…
Alagille syndrome symptoms vary by gene mutation, study finds
People with Alagille syndrome display different disease characteristics depending on whether the disease-causing mutation is located in the JAG1 gene or the NOTCH2 gene,…
New mutation props up woman’s Alagille syndrome diagnosis
An unreported mutation in the JAG1 gene was identified as the likely cause of Alagille syndrome in a 28-year-old woman, a case report from…
Hoth, VA partner on head-to-head study in fatty liver disease mice
Hoth Therapeutics will support a U.S. Department of Veterans Affairs (VA) study testing treatment with glial cell-derived neurotrophic factor (GDNF) against semaglutide in a…
UDCA plus phenobarbital safe, effective for infant cholestasis
Combined treatment with phenobarbital and ursodeoxycholic acid (UDCA) is superior to phenobarbital alone at treating cholestasis symptoms, and does so at a faster rate,…
EMA to review linerixibat for itch in primary biliary cholangitis
The European Medicines Agency (EMA) will review an application for linerixibat, an experimental oral therapy for intense itching associated with primary biliary cholangitis (PBC).